PlGF-3 Antibody (1039018) [Unconjugated]

PlGF-3 was detected in immersion fixed paraffin-embedded sections of human placenta using Mouse Anti-Human PlGF-3 Monoclonal Antibody (Catalog # MAB7758) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to decidual cells. Staining was performed using our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

• Reactivity: Hu
• Applications: IHC
• Clone: 1039018
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

PlGF-3 Antibody (1039018) [Unconjugated] Summary

• Immunogen: Spodoptera frugiperda Sf21 (baculovirus)-derived human PlGF-3
  Leu19-Arg221
  Accession # P49763
• Specificity: Detects human PIGF-3 in direct ELISAs.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for PlGF-3 Antibody (1039018) [Unconjugated]

• PlGF3
• PlGF-3

Background

Placenta growth factor (PlGF or PGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines (1‑3). Alternative splicing likely results in four human mature PlGF forms containing 131 (PlGF‑1), 152 (PlGF‑2), 203 (PlGF‑3), or 224 (PlGF-4) amino acids (aa) (1-3). The PlGF-3 form is limited to humans. PlGF-3 and PlGF-1 do not contain a heparin binding insert at the C‑terminus (1, 2). Within the region shared with other PlGF isoforms (aa 18-131), human PlGF‑3 shares 68%, 66%, 96%, 96%, 87% and 77% aa sequence identity with mouse, rat, porcine, equine, canine and bovine PlGF, respectively. PlGF is mainly found as a variably glycosylated, secreted, 55 ‑ 60 kDa, disulfide linked homodimer (1, 4). Mammalian cells expressing all forms of PlGF include villous trophoblasts and decidual cells, with smaller amounts in erythroblasts, keratinocytes and some endothelial cells (1-3, 5, 6). Circulating PlGF increases during pregnancy, reaching a peak in mid‑gestation; this increase is attenuated in preeclampsia (7). However, deletion of PlGF in the mouse, which expresses only PlGF-2, does not affect development or reproduction (3, 8). Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia (8). PlGF binds and signals through VEGF R1/Flt‑1 and Neuropilins (some isoforms), but not VEGF R2/Flk‑1/KDR (3, 8-10). In contrast, VEGF binds both VEGF R1 and R2, but signals mainly through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, resulting in a PlGF inhibition of VEGF/VEGF R1 binding coupled to a subsequent promotion of VEGF/VEGF R2‑mediated angiogenesis (1, 3, 8, 9). However, PlGF (especially PlGF‑1) and some forms of VEGF can form dimers that can alter the angiogenic effect of VEGF on VEGF R2 (3, 4, 9). PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF (3). These activities facilitate wound and bone fracture healing, and also contribute to inflammation in active sickle cell disease and atherosclerosis (5, 6, 8, 11‑14). Circulating PlGF often correlates with tumor stage and aggressiveness (3, 14, 15).

1. Cao, Y. et al. (1997) Biochem. Biophys. Res. Commun. 235:493.
2. Yang, W. et al. (2003) J. Reprod. Immunol. 60:53.
3. Ribatti, D. (2008) Angiogenesis 11:215.
4. Eriksson, A. et al. (2002) Cancer Cell 1:99.
5. Oura, H. et al. (2003) Blood 101:560.
6. Roncal, C. et al. (2010) Cardiovasc. Res. 86:29.
7. Levine, R.J. et al. (2004) N. Engl. J. Med. 350:672.
8. Carmeliet, P. et al. (2001) Nat. Med. 7:575.
9. Autiero, M. et al. (2003) Nat. Med. 9:936.
10. Migdal, M. et al. (1998) J. Biol. Chem. 273:22272.
11. Perelman, N. et al. (2003) Blood 102:1506.
12. Cianfarani, F. et al. (2006) Am. J. Pathol. 169:1167.
13. Maes, C. et al. (2006) J. Clin. Invest. 116:1230.
14. Fischer, C. et al. (2008) Nat. Rev. Cancer 8:942.
15. Schultze, A. et al. (2012) Clin. Exp. Metastasis Apr 8 [Epub ahead of print].

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P49763()